Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report
Tóm tắt
Perivascular epithelioid cell tumors are defined by the World Health Organization as “a collection of rare mesenchymal tumors composed of histologically and immunohistochemically distinctive perivascular epithelioid cells.” Whereas localized perivascular epithelioid cell tumor is typically benign and treated successfully with surgical resection, prognosis for patients with advanced or metastatic perivascular epithelioid cell tumor is unfavorable, and there is no standard curative treatment. We report a Caucasian case of metastatic perivascular epithelioid cell tumor previously treated with chemotherapy and surgery with elevated surface expression of programmed cell death ligand 1. Based on this result, treatment via immune checkpoint inhibition with the monoclonal antibody pembrolizumab was pursued. After 21 cycles, the patient sustained a complete response. Therapy was stopped after the 40th cycle, and she was moved to surveillance. She remained disease free 19 months off treatment. This case report of a patient with perivascular epithelioid cell tumor treated successfully with programmed cell death protein-1 targeted therapy suggests that programmed cell death ligand-1 levels should be measured in patients with perivascular epithelioid cell tumor and immunotherapy considered for recurrent or metastatic patients. Future phase II/III studies in this disease should focus on sequencing of surgery and immunotherapy with a design of curative intent.
Tài liệu tham khảo
Zamboni G, Pea M, Martignoni G, Zancanaro C, Faccioli G, Gilioli E, et al. Clear cell “sugar” tumor of the pancreas. Am J Surg Pathol. 1996;20(6):722–30.
Pea M, Bonetti F, Zamboni G, Martignoni G, Fiore-Donati L, Doglioni C. Clear cell tumor and angiomyolipoma. Am J Surg Pathol. 1991;15(2):199–200.
Folpe AL, Kwiatkowski DJ. Perivascular epithelioid cell neoplasms: pathology and pathogenesis. Hum Pathol. 2010;41(1):1–15.
Wang Z-S, Xu L, Ma L, Song M-Q, Wu L-Q, Zhou X. Hepatic falciform ligament clear cell myomelanocytic tumor: a case report and a comprehensive review of the literature on perivascular epithelioid cell tumors. BMC Cancer. 2015;15(1):1004.
Conlon N, Soslow RA, Murali R. Perivascular epithelioid tumours (PEComas) of the gynaecological tract. J Clin Pathol. 2015;68(6):418–26.
Wildgruber M, Becker K, Feith M, Gaa J. Perivascular epitheloid cell tumor (PEComa) mimicking retroperitoneal liposarcoma. World J Surg Oncol. 2014;12(1):3.
Zhao L, Anders KH. Malignant perivascular epithelioid cell tumor of the gallbladder: a case report and review of the literature. Arch Pathol Lab Med. 2014;138:1238–41.
Henske EP, Neumann HPH, Scheithauer BW, Herbst EW, Short MP, Kwiatkowski DJ. Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band l6p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosom Cancer. 1995;13(4):295–8.
Smolarek TA, Wessner LL, Mccormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 1998;62(4):810–5.
Wullich B, Henn W, Siemer S, Seitz G, Freiler A, Zang K-D. Clonal chromosome aberrations in three of five sporadic angiomyolipomas of the kidney. Cancer Genet Cytogenet. 1997;96(1):42–5.
Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28(5):835–40.
Lucchesi C, Khalifa E, Laizet YH, Soubeyran I, Mathoulin-Pelissier S, Chomienne C, et al. Targetable alterations in adult patients with soft-tissue sarcomas. JAMA Oncol. 2018;4(10):1398.
Pan C-C, Chung M-Y, Ng K-F, Liu C-Y, Wang J-S, Chai C-Y, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol. 2007;214(3):387–93.
Paydas S, Bagir EK, Deveci MA, Gonlusen G. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol. 2016;33(8):93.
Kim C, Kim EK, Han JW, Chon HJ, Heo SJ, Lee YH, et al. Clinical pattern and implication of PD-L1 expression in soft-tissue sarcoma. J Clin Oncol. 2015;33(15_suppl):10565.
Tawbi HA, Burgess M, Bolejack V, Tine BAV, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493–501.
Burgess MA, Bolejack V, Tine BAV, Schuetze S, Hu J, Dangelo SP, et al. Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): final results of SARC028 and biomarker analyses. J Clin Oncol. 2017;35(15_suppl):11008.
D’Angelo SP, Mahoney MR, Tine BAV, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomized, phase 2 trials. Lancet Oncol. 2018;19(3):416–26.
Toulmonde M, Penel N, Adam J, Chevreau C, Blay J-Y, Cesne AL, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas. JAMA Oncol. 2018;4(1):93.
Italiano A, Delcambre C, Hostein I, Cazeau AL, Marty M, Avril A, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010;21(5):1135–7.
Dickson MA, Schwartz GK, Antonescu CR, Kwiatkowski DJ, Malinowska IA. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer. 2012;132(7):1711–7.
Lattanzi M, Deng F-M, Chiriboga LA, et al. Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. J ImmunoTher Cancer. 2018;6:97.